Applied Therapeutics (APLT) Stock Price, News & Analysis

Company Overview

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation.

The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations.

Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.

Key Stats

• Today's Range: $0.10 to $0.10
• 50-Day Range: $0.10 to $0.10
• 52-Week Range: $0.09 to $1.50
• Volume: N/A
• Average Volume: 7.28 million shs
• Market Capitalization: $15.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Reduce

Applied Therapeutics Stock Analysis - MarketRank™

Applied Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 754th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Applied Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Applied Therapeutics has a consensus price target of $1.00, representing about 870.9% upside from its current price of $0.10.

Amount of Analyst Coverage

Applied Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Applied Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for APLT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied Therapeutics does not currently pay a dividend.

Dividend Growth

Applied Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for APLT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Applied Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Applied Therapeutics is held by insiders.

Percentage Held by Institutions

98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/13/2025
• Today: 8/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APLT
• CIK: 1697532
• Web: www.appliedtherapeutics.com
• Phone: (212) 220-9226
• Fax: N/A
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Applied Therapeutics: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +870.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.62 million
• Net Margins: N/A
• Pretax Margin: -1,813.80%
• Return on Equity: -340.84%
• Return on Assets: -175.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.96
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 15.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.49 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 153,958,000
• Free Float: 151,495,000
• Market Cap: $15.86 million
• Optionable: Optionable
• Beta: 2.08